Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN2 and Valganciclovir in Advanced Solid Tumors
NCT06391918Phase 1Terminated
- Sponsor
- GenVivo
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of GEN2 in solid tumor, sponsored by GenVivo. Primary endpoint: Recommended Phase 2 Dose at 28 days. Started Mar 2024; status: terminated.
02
Drugs
GEN2
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06391918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391918.